Drug repurposing against antibiotic resistant bacterial pathogens,European Journal of Medicinal Chemistry

当前位置： X-MOL 学术 › Eur. J. Med. Chem. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Drug repurposing against antibiotic resistant bacterial pathogens
European Journal of Medicinal Chemistry ( IF 6.0 ) Pub Date : 2024-09-04 , DOI: 10.1016/j.ejmech.2024.116833
Manya Aggarwal ₁ , Anushree Patra ₁ , Ishita Awasthi ₁ , Annu George ₁ , Simran Gagneja ₁ , Varsha Gupta ₂ , Neena Capalash ₃ , Prince Sharma ₁

Affiliation

The growing prevalence of MDR and XDR bacterial pathogens is posing a critical threat to global health. Traditional antibiotic development paths have encountered significant challenges and are drying up thus necessitating innovative approaches. Drug repurposing, which involves identifying new therapeutic applications for existing drugs, offers a promising alternative to combat resistant pathogens. By leveraging pre-existing safety and efficacy data, drug repurposing accelerates the development of new antimicrobial therapy regimes. This review explores the potential of repurposing existing FDA approved drugs against the ESKAPE and other clinically relevant bacterial pathogens and delves into the identification of suitable drug candidates, their mechanisms of action, and the potential for combination therapies. It also describes clinical trials and patent protection of repurposed drugs, offering perspectives on this evolving realm of therapeutic interventions against drug resistance.

中文翻译：

针对抗生素耐药细菌病原体的药物再利用

MDR 和 XDR 细菌病原体的日益流行对全球健康构成了严重威胁。传统的抗生素开发路径遇到了重大挑战，并且正在枯竭，因此需要创新方法。药物再利用，包括确定现有药物的新治疗应用，为对抗耐药病原体提供了一种有前途的替代方案。通过利用预先存在的安全性和有效性数据，药物再利用加速了新的抗菌治疗方案的开发。本综述探讨了重新利用 FDA 批准的针对 ESKAPE 和其他临床相关细菌病原体的现有药物的潜力，并深入探讨了合适的候选药物的识别、它们的作用机制以及联合疗法的潜力。它还描述了再利用药物的临床试验和专利保护，为对抗耐药性的治疗干预这一不断发展的领域提供了观点。

更新日期：2024-09-04

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南